Thursday, June 05, 2025 | 06:57 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Trying to boost acquired Wockhardt portfolio which saw sharp decline in sales during pandemic

reddy, dr reddy's
premium

Apart from favipiravir and remdesivir, DRL has already launched nutraceutical products and hand sanitisers

Sohini Das Mumbai
Hyderabad-based Dr Reddy's Laboratories (DRL) is gearing up for two major launches next month - injectable drug remdesivir for hospitalised Covid-19 patients, and oral drug favipiravir that is given to mild to moderate patients. 

While the company admitted that its India revenues were hit due to lower prescription generation and a sluggish growth in the acquired Wockhardt portfolio, it is bullish on its Covid-19 portfolio nonetheless. 

Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic. Products like azithromycin (common antibiotic used in Covid) have also seen traction, DRL